Werewolf Therapeutics Inc
NASDAQ:HOWL

Watchlist Manager
Werewolf Therapeutics Inc Logo
Werewolf Therapeutics Inc
NASDAQ:HOWL
Watchlist
Price: 0.6303 USD -1.73%
Market Cap: 30.6m USD

Wall Street
Price Targets

HOWL Price Targets Summary
Werewolf Therapeutics Inc

Wall Street analysts forecast HOWL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HOWL is 6.29 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.

Lowest
Price Target
3.03 USD
381% Upside
Average
Price Target
6.29 USD
898% Upside
Highest
Price Target
10.5 USD
1 566% Upside
Werewolf Therapeutics Inc Competitors:
Price Targets
LGND
Ligand Pharmaceuticals Inc
23% Upside
COYA
Coya Therapeutics Inc
220% Upside
002007
Hualan Biological Engineering Inc
23% Upside
VCYT
Veracyte Inc
15% Upside
APLS
Apellis Pharmaceuticals Inc
35% Upside
87S
Roivant Sciences Ltd
15% Upside
NVAX
Novavax Inc
74% Upside
2696
Shanghai Henlius Biotech Inc
52% Upside

Revenue
Forecast

Revenue Estimate
Werewolf Therapeutics Inc

The compound annual growth rate of Werewolf Therapeutics Inc's revenue for the next 4 years is 77%.

N/A
Past Growth
77%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Werewolf Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Werewolf Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HOWL's stock price target?
Price Target
6.29 USD

According to Wall Street analysts, the average 1-year price target for HOWL is 6.29 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.

What is Werewolf Therapeutics Inc's Revenue forecast?
Projected CAGR
77%

The compound annual growth rate of Werewolf Therapeutics Inc's revenue for the next 4 years is 77%.

Back to Top